BridgeMD
New treatment option for Infertility
Official title Investigating Micro-Manipulation Procedures for Assisted Hatching Timing
ClinicalTrials.gov ID: NCT06377917
What this study is testing
- What it's testing
- This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 42, women only
You may be able to join if
- for participants:
- Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo
- \<4 2PNs prior to randomization
- Female partners age \<42 years old at start of VOR cycle
- Normal ovarian reserve:
You likely can't join if
- for participants:
- All patients who do not voluntarily give their written consent for participation
- Patients with a prior failed IVF cycle - defined as no blastocysts
- Patients with a history of more than one failed euploid embryo transfer
- Donor oocyte cycles
- Gestational Carriers
See the full eligibility criteria
- for participants:
- Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo
- \<4 2PNs prior to randomization
- Female partners age \<42 years old at start of VOR cycle
- Normal ovarian reserve:
- AMH ≥ 1.2 ng/mL
- AFC ≥ 8
- FSH ≤ 12IU/L
- BMI \<38
- Patients who desire to transfer the best quality embryo for their embryo transfer.
- for participants:
- All patients who do not voluntarily give their written consent for participation
- Patients with a prior failed IVF cycle - defined as no blastocysts
- Patients with a history of more than one failed euploid embryo transfer
- Donor oocyte cycles
- Gestational Carriers
- Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
- Use of surgical procedures to obtain sperm
- Communicating hydrosalpinges without a plan for surgical correct prior to frozen embryo transfer
- Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \<6mm,), or persistent endometrial fluid
- Single gene disorders, chromosomal translocations, or any other disorders requiring a more detailed embryo genetic analysis than standard PGT-A
The study team makes the final eligibility decision.
Where it's taking place
- Marlton, New Jersey, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 42 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Marlton, New Jersey, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.